298 related articles for article (PubMed ID: 11909903)
1. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
[TBL] [Abstract][Full Text] [Related]
2. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
[TBL] [Abstract][Full Text] [Related]
3. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
Poewe W
J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):430. PubMed ID: 11909897
[No Abstract] [Full Text] [Related]
4. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
5. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
6. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
Wohlfarth K; Kampe K; Bigalke H
Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
10. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
Poewe W; Deuschl G; Nebe A; Feifel E; Wissel J; Benecke R; Kessler KR; Ceballos-Baumann AO; Ohly A; Oertel W; Künig G
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):13-7. PubMed ID: 9436721
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A therapy for cervical dystonia.
Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
[TBL] [Abstract][Full Text] [Related]
14. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
Naumann M; Yakovleff A; Durif F;
J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
Rystedt A; Nyholm D; Naver H
Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
[TBL] [Abstract][Full Text] [Related]
19. Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
Wenzel R; Jones D; Borrego JA
J Clin Pharm Ther; 2007 Aug; 32(4):387-402. PubMed ID: 17635341
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A therapy for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD003633. PubMed ID: 15674910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]